PolyP is one of the oldest biological energy carriers, surpassing ATP in energy storage capacity. Abundant in marine organisms, this polymer plays essential metabolic and regulatory roles and forms biologically active nano/microparticles, making it a promising candidate for biomedical applications. Tissue regeneration, particularly for skin and bone, requires ATP, yet extracellular ATP levels, especially in chronic wounds, are low. PolyP, naturally delivered by blood platelets, compensates for this deficiency, enabling efficient tissue repair. PolyP-stabilized amorphous calcium-phosphate particles exhibit osteoinductive properties and serve as hydroxyapatite precursors, making them ideal for bone regeneration and 3D bone implants. Additionally, polyP stimulates mesenchymal stem cell differentiation into both osteoblasts and chondrocytes, highlighting its role in cartilage repair. Chronic wounds are a major healthcare burden, with treatment costs ranging from $30 to $100 billion annually. PolyP, incorporated into collagen mats or hydrogels, has shown unprecedented success in healing chronic wounds, offering a novel therapeutic option. PolyP uniquely combines metabolic energy delivery with regenerative activity, distinguishing it from traditional biomaterials. Notably, it binds to the SARS-CoV-2 spike protein, suggesting potential as an antiviral agent. Deemed non-toxic by the FDA and EU, polyP (E 452) shows no carcinogenicity or genotoxicity and is GMP-approved for human applications, paving the way for clinical use. PolyP's multifunctionality positions it as a breakthrough biomaterial in regenerative medicine. [Acknowledgements: This work was supported by an ERC Advanced Investigator Grant (grant number: 268476) and three ERC-PoC grants (grant numbers: 324564, 662486 and 767234); W.E.G. Müller is the Investigator.]